StockNews.com Downgrades Voyager Therapeutics (NASDAQ:VYGR) to Hold

Voyager Therapeutics (NASDAQ:VYGR) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

Other analysts have also recently issued reports about the company. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Citigroup assumed coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price on the stock. Wedbush began coverage on Voyager Therapeutics in a report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price target for the company. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $17.00.

Voyager Therapeutics Stock Performance

Shares of Voyager Therapeutics stock opened at $6.27 on Friday. The business has a 50-day simple moving average of $6.59 and a 200-day simple moving average of $7.16. The company has a market cap of $342.53 million, a PE ratio of 8.83 and a beta of 0.90. Voyager Therapeutics has a one year low of $5.19 and a one year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The company had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same period in the prior year, the firm posted ($0.59) EPS. On average, sell-side analysts predict that Voyager Therapeutics will post -0.89 earnings per share for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now owns 86,001 shares in the company, valued at $500,525.82. The trade was a 6.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after acquiring an additional 4,098 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Voyager Therapeutics in the 2nd quarter valued at approximately $85,000. Intech Investment Management LLC purchased a new stake in Voyager Therapeutics in the 3rd quarter valued at approximately $74,000. Victory Capital Management Inc. increased its position in Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after purchasing an additional 1,630 shares during the period. Finally, Hsbc Holdings PLC purchased a new position in shares of Voyager Therapeutics during the 2nd quarter worth approximately $128,000. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.